DDInter1837 DDInter1491
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Toremifene {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Toremifene {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Pomalidomide
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Toremifene {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Toremifene {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Toremifene {u} (Compound) upregulates {v} (Gene) IER3
IER3 {u} (Gene) is downregulated by {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Toremifene may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Toremifene may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) resembles Pomalidomide (Compound)
Toremifene (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pomalidomide (Compound)
Toremifene (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Pomalidomide (Compound)
Toremifene may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide (Compound) resembles Pomalidomide (Compound)
Toremifene may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Toremifene (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Thalidomide (Compound) and Thalidomide (Compound) resembles Pomalidomide (Compound)
Toremifene (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Toremifene (Compound) upregulates IER3 (Gene) and IER3 (Gene) is downregulated by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Toremifene may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Pomalidomide (Compound)